Redirecting to https://torontosun.com/globe-newswire/junshi-biosciences-announces-primary-endpoints-met-in-final-analysis-of-phase-3-study-for-perioperative-toripalimab-plus-chemotherapy-for-resectable-stage-ii-iii-nsclc